Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 10/20 | 0.70 |
| ▸ | NPY4R | P50391 | 8/20 | 0.70 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.70 |
| ▸ | NPY1R | P25929 | 8/20 | 0.70 |
| ▸ | TFPI | P10646 | 4/20 | 0.69 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407563 | 0.89 | PTH1R (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30495701 | 0.87 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29776068 | 0.87 | TFPI (0.65) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29356071 | 0.87 | RAMP3 (0.65) | NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29352518 | 0.87 | RAMP3 (0.65) | NPY2RNPY4RNPY5RNPY1R | |
| Sor-C13 SCHEMBL29926670 | 0.87 | TFPI (0.67) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31183026 | 0.87 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Dirucotide SCHEMBL29359894 | 0.86 | AGTR1 (0.64) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL4331434 | 0.86 | NPY2R (0.75) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31544752 | 0.86 | TFPI (0.60) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119639851-A | Preparation method and application of milk-derived immunomodulatory peptide | 大连工业大学 | 2025-03-18 | — | — | CN | claimed |
| US-20240099984-A1 | A BIODISSOLVABLE FILM FOR LOCALIZED AND EFFICIENT TREATMENT OF VULVODYNIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2024-03-28 | — | — | US | claimed |
| US-12582140-B2 | Method of preparing casein hydrolysate | ARLA FOODS AMBA (DK) | 2026-03-24 | — | — | US | disclosed |
| US-20250134895-A1 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | UNIVERSITY HEALTH NETWORK (CA) | 2025-05-01 | — | — | US | disclosed |
| US-20250109143-A1 | KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| CN-119639851-A | Preparation method and application of milk-derived immunomodulatory peptide | 大连工业大学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2025032440-A1 | KLF2 INDUCING COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4470382-A1 | PLANT EXTRACT AND METHODS COMPRISING THEREOF | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2024-12-04 | — | — | EP | disclosed |
| US-20240264173-A1 | METHOD OF PROGNOSIS | PLAQUETEC LTD. (GB) | 2024-08-08 | — | — | US | disclosed |
| US-20240099984-A1 | A BIODISSOLVABLE FILM FOR LOCALIZED AND EFFICIENT TREATMENT OF VULVODYNIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2024-03-28 | — | — | US | disclosed |
| EP-4341698-A1 | METHOD OF PROGNOSIS | Plaquetec Ltd (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20230276827-A1 | METHOD OF PREPARING CASEIN HYDROLYSATE | ARLA FOODS AMBA (DK) | 2023-09-07 | — | — | US | disclosed |
| US-20230218659-A1 | Selenium-Based Compositions and Therapeutic Methods | HESS PHARMACEUTICALS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-2938328-B1 | MONOLITHIC PHARMACEUTICAL FORM FOR MODIFIED RELEASE OF AN ACTIVE INGREDIENT COMBINATION | HENNIG ARZNEIMITTEL GMBH&CO KG (DE) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023019351-A1 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | UNIVERSITY HEALTH NETWORK (CA) | 2023-02-23 | — | — | WO | disclosed |
| US-20230044257-A1 | COMPOSITIONS AND METHODS FOR ENHANCED UPTAKE OF ACTIVE INGREDIENTS FOR ANIMAL HEALTH AND NUTRITION | AGROSPHERES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2022243703-A1 | METHOD OF PROGNOSIS | PLAQUETEC LTD (GB) | 2022-11-24 | — | — | WO | disclosed |
| EP-4061802-A2 | COMPOSITIONS AND METHODS FOR ENHANCED UPTAKE OF ACTIVE INGREDIENTS FOR ANIMAL HEALTH AND NUTRITION | Agrospheres, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-11346797-B2 | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties | AGILENT TECHNOLOGIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134895-A1 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | SNCA, SAMHD1, MAPT | NPY2R 4666/4885NPY4R 4411/4885NPY5R 3804/4885 |
| US-20250109143-A1 | KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF | KLF5, KLF10, SREBF2 | NPY2R 2683/4885NPY4R 3565/4885NPY5R 3564/4885 |
| US-12582140-B2 | Method of preparing casein hydrolysate | MCRS1, CPN1, CTRL | NPY2R 1371/4885NPY4R 1417/4885NPY5R 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.